(1,3)-ß-D-glucan is able to predict therapeutic failure of patients with candidemia and not only mortality.
Mycoses
; 64(3): 264-271, 2021 Mar.
Article
en En
| MEDLINE
| ID: mdl-33274533
ABSTRACT
BACKGROUND:
Candidemia is a major cause of bloodstream infection in tertiary hospitals worldwide and fungal biomarkers may provide early diagnosis.OBJECTIVES:
To evaluate the performance of (1-3)-ß-D-glucan (BDG) in the diagnosis of candidemia and its ability to predict therapeutic failure. PATIENTS ANDMETHODS:
This was a prospective, multi-centre study conducted in 3 Brazilian hospitals. Clinical outcome was evaluated along 2 weeks of treatment, and therapeutic failure was defined as the occurrence of persistent candidemia, Candida deep-seated infection or death. Baseline BDG detection was performed with the Fungitell® assay (Associates of Cape Cod, Falmouth-USA).RESULTS:
We enrolled a total of 71 patients with candidemia and a control group with 110 healthy volunteers. The sensitivity and specificity of BDG for diagnosing candidemia were as follows 71.8% (95% confidence interval [95% CI] 59.7% - 81.5%) and 98.2% (95% CI 92.9% - 99.7%), respectively. The only predictor of therapeutic failure was a higher BDG value at diagnosis of candidemia; a value > 226 pg/mL predicted failure with sensitivity and specificity of 75% and 78%, respectively.CONCLUSIONS:
A high baseline serum BDG value was associated with therapeutic failure.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Proteoglicanos
/
Insuficiencia del Tratamiento
/
Candidemia
/
Antígenos Fúngicos
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Screening_studies
Límite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
America do sul
/
Brasil
Idioma:
En
Revista:
Mycoses
Asunto de la revista:
MICROBIOLOGIA
Año:
2021
Tipo del documento:
Article
País de afiliación:
Brasil